Pain Medication Recalled Across Canada Over Dosage Error

One lot of JAMP-Pregabalin 50 milligram capsules recalled as some bottles may contain 150 milligram capsules. Health Canada/handout photo

A nationwide recall has been issued for a common pain medication due to dosage issues, Health Canada says.

One lot of bottled JAMP-Pregabalin 50 milligram capsules may mistakenly contain 150 milligram capsules, which could lead to overdose and potentially cause serious or fatal health risks, the May 3 recall notice said.

The affected lot of JAMP-Pregabalin 50 milligram capsules is from lot number 2305012747, has drug identification number (DIN) 02435985, and an expiry date of August 2026.

JAMP-Pregabalin is a pain medication prescribed to adults to treat pain caused by nerve damage from diabetes, shingles, or spinal cord injuries. It is also prescribed for pain associated with fibromyalgia.

The federal health authority said there could be life-threatening consequences associated with taking too much pregabalin or increasing the dosage suddenly.

“Symptoms of pregabalin overdose may include: sudden mood changes, sleepiness, confusion, depression, agitation, restlessness and seizures,” Health Canada said.

Anyone experiencing overdose symptoms is advised to seek immediate medical attention.

“Additionally, taking too much pregabalin while taking drugs that act on the central nervous system, including opioids, has been associated with heart electrical problems, seizures and death,” the recall said.

Those who take pregabalin are advised to check their medication bottles to ensure that they only contain 50 milligram capsules. The 50 milligram capsules are white with “PG” and “50” printed on them in black ink, while the 150 milligram capsules have “PG” and “150” printed on them in black ink.

Consumers are advised to immediately return bottles of medication to their pharmacist if they are unsure of the dosage or if they find any 150 milligram capsules. Those who are unable to return their prescriptions immediately are advised to talk to their pharmacist or doctor for guidance.

The recall said that patients should not suddenly stop taking pregabalin without first consulting their doctor, since doing so could result in withdrawal symptoms such as insomnia, nausea, headache, anxiety, excessive sweating, diarrhea, and convulsions.

Health Canada said they are monitoring the recall and will ensure that corrective and preventive actions are implemented by the manufacturer to prevent this issue from occurring again.

“The Department will inform the public if any new health risks are identified,” the recall said.

Health care professionals, including pharmacists, are asked to check manufacturer bottles of 50 milligram JAMP-Pregabalin before dispensing to patients to ensure that they do not contain 150 milligram capsules.

For any questions about the recall, consumers can contact JAMP Pharma Corp. Any side effects experienced from health products can be reported to Health Canada.